A Clinical Trial Comparing Efficacy and Safety of Insulin Degludec/Liraglutide (IDegLira) Versus Basal-bolus Therapy in Subjects With Type 2 Diabetes Mellitus

NCT02420262 · Completed

Last updated 2026-05-28

This clinical trial compares two diabetes treatments—insulin degludec/liraglutide (IDegLira) and basal-bolus therapy—in adults with type 2 diabetes to evaluate their effects on blood sugar control.

Status Completed The study has finished.

Phase Phase 3 Confirms effectiveness in a large group before approval.

Type Interventional (clinical trial)

Design Randomized, open-label (no blinding) treatment study

Participants 506 people

Who can join Ages 18+ · all sexes

Timeline Started 2015-07 · est. completion 2016-10

Where 117 sites · Argentina, Czechia, France, Greece, Hungary, Israel, Mexico, Russia, Slovakia, Spain, Turkey (Türkiye), United States

What this study is testing ClinicalTrials.gov NCT02420262 ↗

Description as written by the study sponsor.

This trial is conducted globally. The aim of this trial is to compare efficacy and safety of insulin degludec/liraglutide (IDegLira) versus basal-bolus therapy in combination with metformin in subjects with type 2 diabetes mellitus.

Treatments tested

insulin degludec/liraglutide Drug

Once daily injected s.c./subcutaneously (under the skin) in combination with metformin.
insulin glargine Drug

Once daily injected s.c./subcutaneously (under the skin) in combination with metformin.
insulin aspart Drug

Injected s.c./subcutaneously (under the skin) before each main meal.

Main thing measured	Change in HbA1c (Glycosylated Haemoglobin)
Sponsor	Novo Nordisk A/S
Conditions studied	Diabetes, Diabetes Mellitus, Type 2
GLP-1 drugs	liraglutide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT02420262 ↗